IGF1 and metabolic syndrome: Studies reported that during rhGH replacement at a mean dose of 0.5 +/− 0.2 mg/day resulting in IGF-I concentrations in the normal age-adjusted reference range, the prevalence of (components of) the MetS did not change after 2 or 5 years, even 10 years of treatment with rhGH [22, 23].